Mid-stage promise turns to pivotal bust for Immutep
Tacti-004 is terminated for futility, and Immutep crashes 89%.
AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
Kainova bigs up EP4 antagonism
But there are no efficacy data, and the mechanism has a mountain to climb.
Corbus joins Pfizer with integrin no-go
CRB-601 and PF-06940434 fall by the wayside.
Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
BioNTech plans a spin-off
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
